ALLOGENE THERAPEUTICS INC. - COMMON STOCK

Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer

16 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

27 Sep 2023 09:09:21 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in September Investor Conference

05 Sep 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Earl Douglas as General Counsel

14 Aug 2023 08:30:38 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

02 Aug 2023 16:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023

26 Jul 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano

15 Jun 2023 09:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Departure of Chief Financial Officer

14 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano

09 Jun 2023 18:25:18 By Nasdaq GlobeNewswire

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

03 Jun 2023 09:00:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

24 May 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress

11 May 2023 11:50:32 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

03 May 2023 16:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

26 Apr 2023 10:06:38 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023

25 Apr 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer

20 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting

17 Apr 2023 10:15:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences

13 Apr 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report

30 Mar 2023 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting

14 Mar 2023 17:30:48 By Nasdaq GlobeNewswire